^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMM-101

    i
    Other names: IMM-101, IMM 101, heat-killed whole cell Mycobacterium obuense suspension in borate-buffered saline, NCTC 13365, heat killed M. obuense (NCTC) 13365)
    Associations

    News

    Trials
    Company:
    Immodulon
    Drug class:
    Dendritic cell activator
    Related drugs:
    Associations

    News

    Trials
    6ms
    COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
    P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Oct 2023 --> Apr 2024
    Trial primary completion date
    |
    IMM-101
    10ms
    COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
    P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    IMM-101
    over1year
    Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer. (PubMed, Cancers (Basel))
    Combination therapy with SBRT and a heat-killed mycobacterium vaccine was safe and had an immune-stimulatory effect.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • ICOS (Inducible T Cell Costimulator) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M)
    |
    IMM-101
    2years
    IMM-101-015: A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (clinicaltrials.gov)
    P2, N=16, Completed, Immodulon Therapeutics Ltd | Active, not recruiting --> Completed | N=26 --> 16 | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
    over2years
    ANTONIO: Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (clinicaltrials.gov)
    P2, N=120, Recruiting, AIO-Studien-gGmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • oxaliplatin • IMM-101
    over2years
    ANTONIO: Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, AIO-Studien-gGmbH
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • oxaliplatin • IMM-101
    3years
    A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, Immodulon Therapeutics Ltd | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
    over3years
    Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer(MEPANC-1) (clinicaltrialsregister.eu)
    P2, N=100, Ongoing, Erasmus MC
    Clinical • New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    IMM-101